Structure Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 weeks.
- Its last 6 Sell calls were followed by a 13% average decline over the next quarter.
- Recent price momentum is -60.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -11.9% | Better than 19% |
| Return on invested capital | -11.8% | Better than 16% |
Momentum F
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -67.1% | Better than 1% |
| 6-month return | -58.8% | Better than 5% |
| 12-month return (ex latest month) | -36.1% | Better than 7% |
| Distance below 52-week high | 83.0% | Better than 2% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 24.8x | Better than 99% |
| Debt to assets | 0.4% | Better than 96% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 542.7% | Better than 100% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 17.12
- Open
- 16.73
- Day range
- 16.06 - 17.08
- Avg price
- 16.43
- Volume
- 786.24K
- Turnover
- 12.92M
- Turnover ratei
- 1.42%
- Volume ratioi
- 0.88
- Amplitudei
- 5.96%
- 52-week rangei
- 16.06 - 94.90
Valuation
- P/Ei
- -6.72
- P/E (TTM)i
- -4.14
- P/Bi
- 0.95
- EPSi
- -2.40
- Book value / shi
- 17.07
- Net profit
- -171.82M
- Net assets
- 1.22B
Share structure
- Market cap
- 1.15B
- Float capi
- 894.95M
- Shares out
- 71.59M
- Float sharesi
- 55.48M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2023-02-03
83.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-22.22M net over the window
Short interest
- Shares short
- 5.93M
- % of floati
- 8.31%
- Days to coveri
- 6.50
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Structure Therapeutics (GPCR)?
Structure Therapeutics last traded at 16.13. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Structure Therapeutics's market cap?
About 1.15B.
What is the P/E ratio of Structure Therapeutics?
The trailing twelve-month P/E is -4.14. The Valuation tab shows it against the stock's own five-year range.
Does Structure Therapeutics pay a dividend?
Structure Therapeutics does not currently pay a regular dividend.
Is Structure Therapeutics a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 103.67, which implies 542.7% upside from the current price. This is not investment advice.
What is Structure Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Structure Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Structure Therapeutics discussion 0 comments